Navigation Links
Eurofins MWG Operon launches ion proton sequencing services with CSP certification
Date:1/23/2014

Ebersberg, Germany, January 23th, 2014 - Eurofins MWG Operon, a leader in next generation sequencing services has expanded its exome sequencing services with the Ion Proton Next Generation Sequencer.

Certification for Ion AmpliSeq Exome sequencing was also awarded after joining Life Technologies Corporation's Ion AmpliSeq Exome Certified Service Provider (CSP) program. Membership in Life Technologies' CSP program is exclusive and comprises of a select group of genomic service providers worldwide who meet the standards set by Ion Torrent for delivering high-quality sequence data.

Using Life Technologies proprietary approach, consisting of the Ion AmpliSeq Exome Kit, the Ion Proton Sequencer and Ion Reporter Software, provides researchers with the fastest, most cost-effective exome sequencing solution available with flexible throughput on the market today. "Eurofins MWG Operon is pleased to gain exome certification allowing us to offer Life Technologies Ion Proton exome sequencing services to our global customers. This will further aid researchers in their quest to identify disease-causing genes", said Bruno Poddevin, Vice President of Eurofins MWG Operon.


'/>"/>

Contact: Dr. Georg Gradl
georggradl@eurofins.com
49-809-282-89945
Eurofins MWG Operon
Source:Eurekalert  

Page: 1

Related biology news :

1. Eurofins MWG Operon reinforces NGS capability with Illumina HiSeq 2500 and Illumina MiSeq
2. Eurofins MWG Operon and Queen Mary, University Of London commence genome sequencing analysis of Ash
3. Eurofins MWG Operon and Floragenex close co-marketing agreement for RAD discovery and RAD genotyping
4. Eurofins scientists discover genetic differences between identical twins
5. Eurofins and Orion Diagnostica Oy enter into an agreement on Orions proprietary SIBA technology
6. Rice, MD Anderson scientists probe mystery of operon evolution
7. LABS, Inc. Launches Suite of Next-Generation Test Offerings; Focuses on Expanding Complex Biologic Testing Portfolio in 2012
8. Elsevier launches new journal Algal Research
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes
11. WanderID Launches Breakthrough ID Product for Children, Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Eurofins MWG Operon launches ion proton sequencing services with CSP certification
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: